Home > Press > NanoViricides, Inc. Announces Listing in Standard & Poor's Corporation Records and Market Access Program
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that its corporate information is now available via Standard & Poor's ("S&P") Market Access Program. The Company's corporate description was published in the Daily News Section of S&P's Standard Corporation Records on July 31, 2007.
NanoViricides, Inc. Announces Listing in Standard & Poor's Corporation Records and Market Access Program
WEST HAVEN, CT | Posted on August 2nd, 2007
Standard Corporation Records is a recognized securities manual for the "Blue Sky" Standard Manual Exemption for secondary trading in 38 states. As part of S&P's Market Access Program, the Company's corporate information will be made available through S&P's Advisor Insight website ( http://www.advisorinsight.com ). The website provides financial advisors with share price, volume dividends, shares outstanding, company financial position and earnings on thousands of companies.
"Being listed in Standard & Poor's is yet another step in our plan to increase our exposure to the investing community," stated Eugene Seymour, MD, NanoViricide's CEO. "We are very pleased with Standard & Poor's decision to include us in its Corporation Records and initiate coverage of us in its Market Access Program."
About NanoViricides, Inc.
NanoViricides, Inc. ( http:// www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, rabies, dengue fever, HIV, hepatitis C, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors.
Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward looking statements are subject to known and unknown risks, uncertainties and other factors including the availability of adequate financing, the success of the Company's research and development strategy, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors may cause actual results, performance, or achievements of the Company to be different from those expressed or implied by the Company.
For more information, please click here
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference February 17th, 2015
Iran 1st among Islamic Nations in Scientific Production, Nanotechnology February 16th, 2015
Novel nanoparticle therapy promotes wound healing March 27th, 2015
Graphene reduces wear of alumina ceramic March 26th, 2015
Application of Graphene Oxide in Body Implants in Iran March 26th, 2015
Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015
Nanoscale worms provide new route to nano-necklace structures March 29th, 2015
Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015
A first glimpse inside a macroscopic quantum state March 28th, 2015
DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015